Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST101 for Essential Tremor
NCT01332695Phase 2Completed
- Sponsor
- Sonexa Therapeutics
- Start
- Apr 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lucicebtide in essential tremor (ET), sponsored by Sonexa Therapeutics. Started Apr 2011; status: completed.
02
Drugs
lucicebtide
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT01332695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332695.